MAPK1 and COVID-19: Key targets such as EGFR and MAPK1, as well as signaling pathway such as PI3K-Akt and MAPK signaling pathway, may be involved in its regulatory effects.[74] Schisantherin-A is the key active compounds of SMI in the treatment of COVID-19.[74] Schisantherin-A blocks activation of MAPK signaling pathways by suppressing the phosphor pation of ERK.